Compare Johnson & Johnson (JNJ) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs SAP SE — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while SAP SE trades at $214.78 (market cap $238.67B). The key difference: Johnson & Johnson is far larger — about 2.6× SAP SE's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and SAP SE for 118 Days on average.
| JNJ | SAP | |
|---|---|---|
Market Cap | $618.09B | $238.67B |
Volume | 6,050,983 | 2,252,662 |
Sector | Health | Technology |
52-Week High | $278.43 | $280.46 |
52-Week Low | $186.00 | $146.38 |
Typical Hold Time | 129 Days | 118 Days |
Enterprise Value | $646.37B | $237.42B |
Dividend Yield | 2.09% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
SAP trades at $212.4, up 1.08% today, with a bullish technical signal and strong fundamentals. Revenue grew to $36.8B in 2025, with net income of $7.16B and a 20.41% margin. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026. Analyst consensus is a Buy with a $253.40 price target. Cloud revenue growth and AI initiatives are key drivers, though competition and margin pressures pose risks.
The outlook is positive, supported by robust cash flow and a €10B buyback program. Upside potential exists if AI and cloud strategies deliver, but execution risks and market volatility could hinder gains. Investors should weigh strong profitability against sector headwinds and valuation multiples above industry averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
